Skip to main content
| News

Sumitovant acquires all shares in Myovant

24.10.2022

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding in the company for 27 dollars per share. As such, this transaction values the company at 2.9 billion US dollars overall. At present, Sumitovant has a stake of 52 percent in Myovant.

The US biopharmaceutical company Sumitovant, headquartered in New York, is to acquire all remaining shares in the Basel-based firm Myovant Sciences that it does not currently hold for 27 US dollars per share. This agreement has now been struck by Sumitovant Biopharma Ltd with the Japanese parent company Sumitomo Pharma and Myovant Sciences, further details of which can be found in a press release.

In this context, the company as a whole is valued at 2.9 billion US dollars, with the value of this transaction amounting to 1.7 billion US dollars overall. At present, Sumitovant holds 52 percent of the issued and outstanding shares of Myovant.

The transaction looks set to be closed in the first quarter of 2023, subject to the approval of regulatory authorities and Myovant shareholders, who hold a majority of the outstanding shares. Upon completion of the acquisition, Myovant’s shares will no longer be listed on the New York Stock Exchange. Sumitovant and Myovant were both founded as subsidiaries of the parent company Roivant, which has its global headquarters in Basel.

Accelerating Myovant’s product pipeline

The agreement has been approved by the boards of Sumitovant and Sumitomo Pharma in addition to the full Board of Directors of Myovant. The takeover is intended to accelerate the development of Myovant’s product pipeline in the areas of women’s health and prostate cancer.

“We look forward to harnessing the combined strength of our talented teams to bring needed therapies to patients sooner and are confident both Myovant and its employees will benefit from the greater resources Sumitovant can provide to further support business growth and career opportunities overall”, comments Myrtle Potter, CEO of Sumitovant, in the press release.

You may also be interested in

KUORI developing biodegradable plastics
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Cell and gene therapies gain momentum in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
AMR Action Fund invests in new antibiotics developed by BioVersys
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Investors give Resistell 8.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 40